Nineteen novel drugs have been selected for inclusion in the first iteration of China's Commercial Health Insurance Innovative Drug Catalogue, portending potential access benefits as the program ga | ...

UCB plans to file for regulatory approval of Fintepla to treat a third epileptic condition “as soon as possible,” the company ...

Amgen is getting the ball rolling on a far-reaching new partnership that’s set to boost its profile in its hometown of ...

With T-cell engagers already established as late-line therapies for certain blood cancers, Regeneron has released early data ...